Arexvy is currently approved as a single dose to protect against symptomatic lower respiratory tract disease caused by RSV in adults aged 60 years and older.

Those adults aged 60 years and older who are at higher risk of severe RSV disease include:
• people with chronic medical conditions including: respiratory, cardiovascular, neurological, haematological conditions, diabetes, or liver or kidney disorders
• people with moderate or severe immune compromise
• people who are frail
• people aged over 80 years*
• people living in nursing homes or other long-term care facilities
• older people of Maori and Pacific ethnicity, especially if living in areas of high deprivation

*The risk of severe RSV among adults increases with age, with the highest rates of hospitalisation among those aged 75 years and older. Although age may be considered in determining an older adult patient’s risk for severe RSV-associated disease, there is no specific age threshold at which RSV vaccination is universally recommended within the age group of adults ages 60 years and older.
The cost is $345.00 + $40 nurse fee ($19.50 if CSC holder and $50.00 if casual patient)
The vaccine must be paid for on the day of your appointment

Visit the Immunisation Advisory Centre for more information on the vaccine. https://www.immune.org.nz/vaccine/arexvy

To book a nurse appointment please call our reception team on 04 471 2161